Capricor Therapeutics announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet on July 29, 2026, to review its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD). The application is supported by positive Phase 2 and Phase 3 trial results showing significant benefits in muscle and heart function. The FDA's decision is expected by August 22, 2026. This meeting is a key step toward potentially approving the first-in-class treatment for DMD, a severe genetic disorder with limited options.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Bitget has introduced a Cross-Asset Unified Account that integrates over 370 assets, including 100 tokenized US stocks (rTokens), into a single margin pool. This allows users to use tokenized stocks as margin for futures and margin trading, borrow st...
Researchers from Stanford and Singapore Management University discovered that 821 traders manipulated Polymarket’s five-minute Bitcoin contracts by pushing Binance’s spot price just before settlement, extracting $8.2 million. This manipulation occurr...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Thunder Gold Corp. announced results from six diamond drill holes at its Tower Mountain Property in Ontario, confirming the continuation of gold mineralization at depth and identifying new near-surface zones previously considered waste. Key highlight...
